Hypothesis\nIntermittent, low‑dose analgesic regimens that allow brief bouts of nociceptive signaling preserve the hormetic activation of stress‑resilience pathways (e.g., Nrf2, PGC‑1α, autophagy) while preventing the transition to chronic inflammatory sensitization, thereby extending healthspan and lifespan.\n\n## Mechanistic Rationale\nAcute pain triggers COX‑2–derived prostaglandin E2, raising cAMP and activating PKA‑CREB signaling. In short bursts this cascade phosphorylates Nrf2, promoting antioxidant gene expression, and stimulates PGC‑1α‑mediated mitochondrial biogenesis [5][6]. When analgesia is continuous, these transient spikes are blunted, reducing the hormetic boost to antioxidant defenses and mitochondrial turnover. Conversely, unmitigated chronic pain sustains NF‑κB activity, elevating IL‑6, TNF‑α, and ROS, which drives inflammaging and accelerates senescence [1][2]. Intermittent dosing creates a square‑wave pattern: each analgesic gap permits a controlled pain pulse that activates repair pathways, while the drug‑on phases keep cumulative inflammatory load below the threshold for maladaptive sensitization.\n\nNovel insight: the analgesic gap length should match the decay constant of prostaglandin E2 (~2–4 h) to capture the Nrf2 activation window without allowing COX‑2‑driven PGES feedback that fuels chronic inflammation. This timing can be derived from pharmacokinetic models of NSAIDs (e.g., ibuprofen half‑life ≈2 h) and predicts that dosing every 6 h with a 2‑h drug‑free interval yields optimal hormesis.\n\n## Testable Predictions\n1. Mice receiving ibuprofen on a 6‑on/2‑off schedule will show higher hepatic Nrf2 target gene expression (Nqo1, Ho‑1) and increased PGC‑1α protein levels compared with continuous dosing or no drug, while maintaining plasma IL‑6 at baseline levels.\n2. The intermittent group will exhibit improved grip strength and treadmill endurance at 18 months of age, reflecting preserved muscle mitochondrial function.\n3. Chronic pain model (CFA‑induced) mice given the same intermittent regimen will develop less secondary mechanical hypersensitivity than continuously treated counterparts, indicating prevention of maladaptive sensitization.\n4. Lifespan analysis will reveal a significant extension of median survival in the intermittent group relative to continuous dosing (hazard ratio <0.8, p<0.05) and comparable to caloric restriction controls.\n\n## Potential Experimental Design\n- Use male C57BL/6J mice, n=30 per group: (i) control (vehicle), (ii) continuous ibuprofen (50 mg/kg/day in food), (iii) intermittent ibuprofen (same total weekly dose split into 6 h on/2 h off cycles), (iv) caloric restriction (40% reduction).\n- Induce mild nociceptive tone with weekly low‑dose capsaicin (0.1 mg/kg, i.p.) to mimic physiological pain bursts.\n- Measure serum PGE2, IL‑6, TNF‑α at 0, 2, 4, 6 h after each dosing cycle; assess hepatic Nrf2 nuclear translocation, PGC‑1α, LC3‑II/I ratios via Western blot.\n- Behavioral phenotyping monthly (grip strength, rotarod, treadmill).\n- Survival monitoring until natural death; statistical analysis with Cox proportional hazards model.\n\nIf intermittent analgesia preserves hormetic signaling without accruing inflammatory load, this approach would reframe pain management from blunt suppression to timed, signal‑preserving modulation, directly testing the hypothesis that physiologic pain pulses are necessary longevity cues.
